Neurocrine biosciences presents data on sleep disturbances and off time in patients with parkinson's disease and motor fluctuations at sleep 2022

San diego , june 6, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today presents data on sleep disturbances in parkinson's disease (pd) demonstrating the impact of off episodes, or reemergence of symptoms between doses of levodopa, on falling asleep and staying asleep. these data (abstract id: 0581) are being shared at sleep 2022, the annual meeting of the associated professional sleep societies, llc (apss) being held june 4-8 in charlotte, north carolina.
NBIX Ratings Summary
NBIX Quant Ranking